AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.41 USD
+0.42 (6.01%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.24 -0.17 (-2.29%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.41 USD
+0.42 (6.01%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.24 -0.17 (-2.29%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Zacks News
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.
Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong segmental performance.
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
by Zacks Equity Research
Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.
DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated
by Zacks Equity Research
Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.
AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improved in Q2.
CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3
Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
AngioDynamics (ANGO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Add AngioDynamics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.
AngioDynamics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AngioDynamics.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.
AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
AngioDynamics (ANGO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Unveils Auryon Atherectomy System for PAD
by Zacks Equity Research
AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.
Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for August 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for August 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
by Zacks Equity Research
AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
AngioDynamics (ANGO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?